In­dus­try speaks out against ICER's sug­gest­ed up­dates to as­sess­ment frame­work

Drug­mak­ers and in­dus­try groups have crit­i­cized the In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view af­ter the cost-ef­fec­tive­ness watch­dog said it may con­sid­er low­er­ing the thresh­old for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER